ChromaDex Corp. announced today that the initial results of the first human clinical study for the company's NIAGEN nicotinamide riboside (NR) has met its primary endpoint.
from The Medical News http://ift.tt/1z7fb9u
from The Medical News http://ift.tt/1z7fb9u
No comments:
Post a Comment